FierceHealthcare FierceHealthIT FierceMobileHealthcare FierceHealthPayer
FierceHealthFinance FierceEMR FiercePracticeManagemtn Hospital Impact

Syndicate content

Cancer Vaccine news from FierceHealthcare

News

ALSO NOTED: Tenet sells two hospitals; Health IT M&A market still hot; and much more...

> Tenet announced that it will sell two hospitals to the University of Southern California. Article > Things may be Read more...

ALSO NOTED: States sue Abbott, claiming it blocked generics; SEC helps troubled hospital bond holders; and much more...

> Eighteen states are suing Abbott Laboratories, saying it blocked generic competition for its popular cholesterol medication TriCor. Read more...

Press Releases

Biovest to Present on Regulatory Strategy for BiovaxID® Cancer Vaccine at MD Becker Cancer Immunotherapy Conference

TAMPA, Fla. & MINNEAPOLIS, Minn.--(BUSINESS WIRE)-- Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Read more >>

ImmunoCellular Therapeutics’ ICT-107 Named One of the 100 Great Investigational Drugs for 2011

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, Read more >>

Biovest Issues Post-ASH Update for BiovaxID® Personalized Cancer Vaccine including Significance of Isotype Phase III Data

Files Annual Report and Reports Antibody Manufacturing Contract TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)-- Biovest International, Inc. (OTCQB: “BVTI”) today issued the following update in the Read more >>

PROFNET EXPERT ALERTS: Cancer Vaccines / Organ Donation / Online Privacy

May 28, 2010Health: Cutting-Edge Advancements in the Cancer Vaccine IndustryHealth: Health Care Facilities Need Correctly Trained Support StaffHealth: Impact of a Presumed-Consent Law on Organ Read more >>

IRX Therapeutics Announces Cancer Vaccine Collaboration with Japan’s National Cancer Research Center

IRX-2 Immunomodulator Selected for Use in Proof-of-Concept Clinical Trials in Multiple Cancer Indications NEW YORK--(BUSINESS WIRE)-- IRX Therapeutics, a developer of novel immunomodulators to treat Read more >>